The Humanistic Burden and Productivity Lost From Atopic Dermatitis in Central and Eastern European Countries

Speaker(s)

Elezbawy B1, Kalo Z2, Fasseeh A3, Inotai A4, Németh B5, Agh T6
11) Semmelweis University, Hungary; 2) Syreon Middle East, Alexandria, ALX, Egypt, 21. Semmelweis University, Center for Health Technology Assessment; 2. Syreon Research Institute, Budapest, PE, Hungary, 31) Faculty of Pharmacy Alexandria University 2) Syreon Middle East, Alexandria, Egypt, 41. Semmelweis University, Center for Health Technology Assessment; 2. Syreon Research Institute, Budapest, Hungary, 5Syreon Research Institute, Budapest, Hungary, 6Syreon Research Institute, Budapest, PE, Hungary

Presentation Documents

OBJECTIVES: Atopic dermatitis (AD) significantly impacts quality of life and productivity, contributing to a hidden burden. This study aims to quantify this burden in adults and adolescents across Central and Eastern European (CEE) countries.

METHODS: A disease burden model was developed to provide a quantitative assessment of the hidden burden of AD in CEE countries. A bottom-up approach was employed to estimate the burden. The humanistic burden was quantified by calculating the monetary value of quality-adjusted life years (QALYs) lost, using the number of adult and adolescent patients in each country and the corresponding gross domestic product (GDP) per capita. The indirect economic burden was assessed through productivity losses. The overall hidden burden was determined by summing the productivity losses and the monetary value of QALYs lost for each country.

RESULTS: Annual QALY losses due to AD in CEE countries ranged from 1,832 to 58,596. This translated into a monetary loss of 38 million to approximately 1 billion EUR per country. Productivity losses resulted in additional annual economic losses of 3.6 to 148.9 million EUR. The total hidden burden of AD accounted for 0.11% to 0.43% of the GDP, depending on the country.

CONCLUSIONS: The significant variations in our estimates highlight the differences in population sizes, AD prevalence rates, and economic strengths among CEE countries. By adjusting our findings to each country's GDP, we obtained a clearer picture of the hidden burden of AD. This information is crucial for decision-makers in CEE countries to prioritize and make informed, evidence-based decisions.

Code

EPH130

Topic

Economic Evaluation, Patient-Centered Research

Topic Subcategory

Patient-reported Outcomes & Quality of Life Outcomes, Work & Home Productivity - Indirect Costs

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Sensory System Disorders (Ear, Eye, Dental, Skin)